Bridging the gap – estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel

Harries, Manuela; Jaeger, Veronika K.; Rodiah, Isti; Hassenstein, Max J.; Ortmann, Julia; Dreier, Maren; Holt, Isabell von; Brinkmann, Melanie; Dulovic, Alex; Gornyk, Daniela; Hovardovska, Olga; Kuczewski, C; Kurosinki, MA; Schlotz, Maike; Schneiderhan‐Marra, Nicole; Strengert, Monika; Krause, Gérard; Sester, Martina; Klein, Florian; Petersmann, Astrid; Karch, André; Lange, Berit

doi:10.1101/2022.12.30.22284061

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Having determined that RSV antibody titers appear stable from age 5 onwards, we next assessed long-term antibody presence by evaluating a longitudinal cohort of 190 individuals who donated samples in 2021 and 2022 (separated by 13-15 months) from the MuSPAD cohort, a German supraregional population-based cohort [25], adapted as an epidemic panel [26, 27]. To avoid including any individuals who had experienced infections between samplings, we excluded anyone who had a change in titer greater than 25% from 2021 to 2022 for both post-F and N (9% of samples).…”

Section: Resultsmentioning

confidence: 99%

“…To avoid including any individuals who had experienced infections between samplings, we excluded anyone who had a change in titer greater than 25% from 2021 to 2022 for both post-F and N (9% of samples). Overall, both post-F and N titers were highly stable, decreasing by 8.6% (0.5 – 15.4) and 9.5% (1.7 – 19.2),[26] respectively ( Figure 4c and d ). There was no significant effect of age upon rate of decay for either post-F or N (all p=0.99, Figure 4e and f ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Development and validation of a respiratory syncytial virus multiplex immunoassay

Marsall,

Fandrich,

Griesbaum

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. RSV exists as two subtypes A and B, which co-circulate throughout the season, although one will usually become dominant. While vaccines and monoclonal thera-peutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses anti-body titers towards the post-F, Nucleoprotein, and a diverse mix of G proteins. Technical and clinical validation showed outstanding performance, while methodological developments ena-bled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age-dependent antibody re-sponses within population cohorts. Overall, the developed assay shows robust performance, is scaleable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Development and validation of a respiratory syncytial virus multiplex immunoassay

Marsall,

Fandrich,

Griesbaum

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, such analyses were within the scope of some of the participating studies. There, an increasing activity of neutralising antibodies against the S-antigen for Wuhan and BA.5 variants could be detected with higher categories of the combined endpoint (26). The extent to which an antibody response is actually associated with a protective effect against infection or a severe course after infection is strongly dependent on the SARS-CoV-2 variant circulating.…”

Section: Discussionmentioning

confidence: 99%

Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project

Lange

Jaeger

Harries

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Despite the need to generate valid and reliable estimates of protection against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real-time. In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n=33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses ("confirmed exposures"). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest. Most participants were seropositive against the spike antigen; 37% of the participants ≥79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46-56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4%-28% of participants having less than three confirmed exposures. Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.

show abstract

Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project

Lange,

Jaeger,

Harries

et al. 2023

Infection

View full text Add to dashboard Cite

Purpose Despite the need to generate valid and reliable estimates of protection levels against SARS-CoV-2 infection and severe course of COVID-19 for the German population in summer 2022, there was a lack of systematically collected population-based data allowing for the assessment of the protection level in real time. Methods In the IMMUNEBRIDGE project, we harmonised data and biosamples for nine population-/hospital-based studies (total number of participants n = 33,637) to provide estimates for protection levels against SARS-CoV-2 infection and severe COVID-19 between June and November 2022. Based on evidence synthesis, we formed a combined endpoint of protection levels based on the number of self-reported infections/vaccinations in combination with nucleocapsid/spike antibody responses (“confirmed exposures”). Four confirmed exposures represented the highest protection level, and no exposure represented the lowest. Results Most participants were seropositive against the spike antigen; 37% of the participants ≥ 79 years had less than four confirmed exposures (highest level of protection) and 5% less than three. In the subgroup of participants with comorbidities, 46–56% had less than four confirmed exposures. We found major heterogeneity across federal states, with 4–28% of participants having less than three confirmed exposures. Conclusion Using serological analyses, literature synthesis and infection dynamics during the survey period, we observed moderate to high levels of protection against severe COVID-19, whereas the protection against SARS-CoV-2 infection was low across all age groups. We found relevant protection gaps in the oldest age group and amongst individuals with comorbidities, indicating a need for additional protective measures in these groups.

show abstract

Bridging the gap – estimation of 2022/2023 SARS-CoV-2 healthcare burden in Germany based on multidimensional data from a rapid epidemic panel

Cited by 3 publications

References 30 publications

Development and validation of a respiratory syncytial virus multiplex immunoassay

Development and validation of a respiratory syncytial virus multiplex immunoassay

Estimates of protection against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season - the IMMUNEBRIDGE project

Estimates of protection levels against SARS-CoV-2 infection and severe COVID-19 in Germany before the 2022/2023 winter season: the IMMUNEBRIDGE project

Contact Info

Product

Resources

About